[HTML][HTML] Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
JA Chan, K Stuart, CC Earle, JW Clark… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.gov
Purpose Both tyrosine kinase inhibitors targeting the vascular endothelial growth factor
(VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have antitumor
activity in neuroendocrine tumors (NETs). Temozolomide, an oral analog of dacarbazine,
also has activity against NETs when administered alone or in combination with other agents.
We performed a phase II study to evaluate the efficacy of temozolomide in combination with
bevacizumab in patients with locally advanced or metastatic NETs.
(VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have antitumor
activity in neuroendocrine tumors (NETs). Temozolomide, an oral analog of dacarbazine,
also has activity against NETs when administered alone or in combination with other agents.
We performed a phase II study to evaluate the efficacy of temozolomide in combination with
bevacizumab in patients with locally advanced or metastatic NETs.
Abstract
Purpose
Both tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have antitumor activity in neuroendocrine tumors (NETs). Temozolomide, an oral analog of dacarbazine, also has activity against NETs when administered alone or in combination with other agents. We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs.
ncbi.nlm.nih.gov